Press Releases

01-12 Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes GL
01-09 UPC's Court Of Appeal Overturns First Instance Decision In Amgen V. Sanofi And Regeneron AQ
01-05 Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes GL
12-25 Sanofi acquires Dynavax and strengthens its vaccine portfolio AQ
12-24 US stocks drift to more records on a holiday-shortened day of trading AQ
12-24 Local Organ, Eye and Tissue Donors, Transplant Recipients and Living Donors to be Honored on the 2026 OneLegacy Donate Life Rose Parade(R) Float on New Year's Day AQ
12-24 Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline GL
12-24 Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis GL
12-23 Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia GL
12-23 Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma GL
12-22 Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025 PU
12-19 Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation GL
12-18 Cytokinetics Announces NMPA Approval of MYQORZO in China for Patients with Obstructive Hypertrophic Cardiomyopathy AQ
12-18 Claiming Your Drug Product Is Unique: Does That Mean It's Superior? AQ
12-17 Availability of the Q4 2025 Aide memoire GL
12-17 Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema GL
12-15 Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis GL
12-15 Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis GL
12-11 Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases GL
12-09 FDA opens safety review of injectable RSV drugs approved for babies and toddlers AQ
12-04 Sanofi completes acquisition of Vicebio GL
12-03 UPC Court Of Appeal Overturns Revocation Of Amgen's PCSK9 Antibody Patent And Clarifies The UPC's Inventive Step Approach (Amgen v Sanofi And Regeneron) AQ
11-28 Sanofi invests 50 million euros in its Le Trait site to meet growing demand for anti-inflammatory drug Dupixent AQ
11-25 Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria GL
11-19 Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors AQ
No results for this search